Regenera (Biotechnology) Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC
  • (Cancelled)

  • Latest Deal Amount
  • $13.3M

  • Investors
  • 2

Regenera (Biotechnology) General Information

Description

Developer of a combined biomaterial and stem cell therapy designed for sub-acute spinal cord injury repair. The company's platform integrates an injectable resorbable hydrogel with autologous stem cells to provide trophic support to tissue plasticity, enabling the healthcare market to progressively lead damaged tissue toward self-regeneration and achieve cord functionality restoration.

Contact Information

Website
www.regenera.at
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Modecenterstrasse 22/D01
  • Vienna, Vienna 1030
  • Austria
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Other Healthcare Services
Vertical(s)
Corporate Office
  • Modecenterstrasse 22/D01
  • Vienna, Vienna 1030
  • Austria

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regenera (Biotechnology) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 20-Sep-2024 $13.3M Cancelled Startup
2. Accelerator/Incubator 28-Sep-2022 Completed Startup
1. Seed Round 11-Apr-2022 Completed Startup
To view Regenera (Biotechnology)’s complete valuation and funding history, request access »

Regenera (Biotechnology) Patents

Regenera (Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4777161-A1 A double interpenetrating polymeric matrix hydrogel containing progenitor cells and biomolecules, for neuronal tissue repair Pending 12-Sep-2023
WO-2025056722-A1 A double interpenetrating polymeric matrix hydrogel containing progenitor cells and biomolecules, for neuronal tissue repair Inactive 12-Sep-2023
JP-2026532214-A A dual interpenetrating polymer matrix hydrogel for nerve tissue repair, containing progenitor cells and biomolecules. Pending 12-Sep-2023 A61K47/32

Regenera (Biotechnology) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regenera (Biotechnology) Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
USI Startup Centre Accelerator/Incubator
ILUM Tec GmbH Corporation Minority
To view Regenera (Biotechnology)’s complete investors history, request access »

Regenera (Biotechnology) FAQs

  • When was Regenera (Biotechnology) founded?

    Regenera (Biotechnology) was founded in 2021.

  • Where is Regenera (Biotechnology) headquartered?

    Regenera (Biotechnology) is headquartered in Vienna, Austria.

  • What is the size of Regenera (Biotechnology)?

    Regenera (Biotechnology) has 4 total employees.

  • What industry is Regenera (Biotechnology) in?

    Regenera (Biotechnology)’s primary industry is Biotechnology.

  • Is Regenera (Biotechnology) a private or public company?

    Regenera (Biotechnology) is a Private company.

  • What is Regenera (Biotechnology)’s current revenue?

    The current revenue for Regenera (Biotechnology) is .

  • Who are Regenera (Biotechnology)’s investors?

    USI Startup Centre and ILUM Tec GmbH have invested in Regenera (Biotechnology).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process